Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: Alemtuzumab
Drug: Etoposide
Drug: Dexamethasone
Drug: Methotrexate
Behavioral: Phone Call
Drug: Tocilizumab

First Posted Date: 2015-03-11

Last Posted Date: 2024-01-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 18

Registration Number: NCT02385110

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors

Phase 2

Terminated

Conditions: Optic Glioma
Astrocytoma
Pilocytic Astrocytoma
Anaplastic Astrocytoma
Glioblastoma
Glioma
Mixed Oligoastrocytoma
Mixed Glioma
Oligodendroglioma

Interventions: Device: MRI-guided laser ablation
Device: Dynamic contrast-enhanced (DCE) MRI
Drug: Doxorubicin
Device: Dynamic susceptibility contrast (DSC) MRI
Drug: Etoposide

First Posted Date: 2015-02-26

Last Posted Date: 2024-11-01

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 6

Registration Number: NCT02372409

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL

Phase 3

Terminated

Conditions: Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma

Interventions: Radiation: 90-Yttrium Ibritumomab tiuxetan
Drug: Carmustine
Drug: Etoposide
Drug: Cytarabine
Drug: Melphalan
Procedure: Autologous Hematopoietic Stem Cell Transplant
Biological: Rituximab

First Posted Date: 2015-02-19

Last Posted Date: 2018-03-12

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 3

Registration Number: NCT02366663

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage

Phase 3

Terminated

Conditions: Lymphoma, Extranodal NK-T-Cell

Interventions: Drug: Gemcitabine
Drug: Etoposide
Drug: Oxaliplatin
Drug: Vincristine
Drug: Pegaspargase
Drug: Doxorubicin
Radiation: IMRT
Drug: Cyclophosphamide
Drug: Prednisone

First Posted Date: 2015-02-09

Last Posted Date: 2018-05-09

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 50

Registration Number: NCT02359162

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, GuangZhou, Guangdong, China

Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer

Phase 4

Conditions: Small Cell Lung Cancer

Interventions: Drug: Etoposide
Drug: Irinotecan
Drug: Cisplatin

First Posted Date: 2015-01-28

Last Posted Date: 2016-12-05

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 308

Registration Number: NCT02348450

Locations: 🇨🇳
WuHan Tongji Hospital, WuHan, Hubei, China
🇨🇳
LiaoNing Provincial Tumor Hospital, Shenyang, Liaoning, China
🇨🇳
The second affiliated hospital of zhejiang university school of medicine, Hangzhou, Zhejiang, China

and more 17 locations

Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT

Phase 2

Terminated

Conditions: Leukemia, Acute Lymphoblastic
Acute Myeloid Leukemia

Interventions: Drug: Clofarabine
Drug: Cyclophosphamide
Drug: Etoposide

First Posted Date: 2015-01-28

Last Posted Date: 2020-03-09

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 6

Registration Number: NCT02349178

Locations: 🇺🇸
Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸
Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin, United States
🇺🇸
American Family Children's Hospital, Madison, Wisconsin, United States

and more 1 locations

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Phase 1

Completed

Conditions: Primary Mediastinal B-cell Lymphoma (PMBCL)
Transformed Follicular Lymphoma (TFL)
High Grade B-cell Lymphoma (HGBCL)
Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Relapsed Diffuse Large B-Cell Lymphoma

Interventions: Biological: Axicabtagene Ciloleucel
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Levetiracetam
Drug: Tocilizumab
Drug: Dexamethasone
Drug: Doxorubicin
Drug: High-dose methylprednisolone
Drug: Prednisone
Drug: Bendamustine
Drug: Vincristine
Drug: Rituximab
Drug: Ifosfamide
Drug: Carboplatin
Drug: Methylprednisolone
Drug: Etoposide
Drug: Gemcitabine
Drug: Oxaliplatin
Drug: Cisplatin

First Posted Date: 2015-01-28

Last Posted Date: 2024-06-04

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 307

Registration Number: NCT02348216

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
University of California Los Angeles (UCLA), Santa Monica, California, United States
🇨🇦
Princess Margaret, Toronto, Ontario, Canada

and more 33 locations

Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma

Phase 1

Active, not recruiting

Conditions: Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma
Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma

Interventions: Biological: Yttrium Y 90 Basiliximab
Drug: Carmustine
Drug: Etoposide
Drug: Cytarabine
Drug: Melphalan
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study

First Posted Date: 2015-01-21

Last Posted Date: 2024-03-19

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 20

Registration Number: NCT02342782

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma

Phase 1

Active, not recruiting

Conditions: AIDS-Related Burkitt Lymphoma
HIV Infection
AIDS Related Non-Hodgkin Lymphoma
AIDS-Related Primary Effusion Lymphoma
AIDS-Related Diffuse Large B-cell Lymphoma
AIDS-Related Plasmablastic Lymphoma

Interventions: Drug: Prednisone
Biological: Rituximab
Drug: Etoposide
Drug: Doxorubicin Hydrochloride
Drug: Vincristine Sulfate
Drug: Cyclophosphamide
Biological: Filgrastim
Biological: Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells

First Posted Date: 2015-01-14

Last Posted Date: 2024-01-30

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 10

Registration Number: NCT02337985

Locations: 🇺🇸
NCI Lymphoid Malignancies Branch, Bethesda, Maryland, United States

Comparison of SEEOX and SOX Regimens in Stage ⅢB/ⅢC Gastric Cancer Patients

Phase 3

Active, not recruiting

Conditions: Stomach Neoplasms
Gastric Cancer

Interventions: Drug: oxaliplatin
Drug: etoposide
Drug: pharmorubicin
Drug: S-1

First Posted Date: 2015-01-14

Last Posted Date: 2023-09-29

Lead Sponsor: Jinling Hospital, China

Target Recruit Count: 297

Registration Number: NCT02338518

Locations: 🇨🇳
Jinling Hospital, Nanjing, Jiangsu, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy